Literature DB >> 17221182

The burden of type 2 diabetes in Serbia and the cost-effectiveness of its management.

Vesna Bjegovic1, Zorica Terzic, Jelena Marinkovic, Nebojsa Lalic, Sandra Sipetic, Ulrich Laaser.   

Abstract

The purpose of this study was to analyse whether the nationwide application of the national Serbian guideline for diabetes mellitus (NSGDM) would save a relevant amount of disability-adjusted life years (DALYs) and/or reduce the medical cost of treating diabetic patients in Serbia, as compared to the present situation. Disability-adjusted life years were calculated for Serbia and the cost-effectiveness was analysed in eight population groups under ideal and present conditions; prevalent and incident cases were each split up for patients with blood glucose that was well controlled and that was uncontrolled. Under ideal conditions, i.e., according to the NSGDM, 8,031 DALYs could be saved with a potential cost reduction at the same time of approximately 19 million Euros. The implementation of the NSGDM in clinical practice bears a great potential to save lives and reduce years lived with lowered quality of life, but in addition it may reduce costs by about a quarter.

Entities:  

Mesh:

Year:  2007        PMID: 17221182     DOI: 10.1007/s10198-006-0012-7

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  10 in total

1.  Prevention of diabetes-related foot ulcers and amputations: a cost-utility analysis based on Markov model simulations.

Authors:  G Ragnarson Tennvall; J Apelqvist
Journal:  Diabetologia       Date:  2001-11       Impact factor: 10.122

2.  Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.

Authors: 
Journal:  JAMA       Date:  2002-05-15       Impact factor: 56.272

3.  Hospitalizations, nursing home admissions, and deaths attributable to diabetes.

Authors:  Louise B Russell; Elmira Valiyeva; Sheila H Roman; Leonard M Pogach; Dong-Churl Suh; Monika M Safford
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

4.  Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.

Authors:  H King; R E Aubert; W H Herman
Journal:  Diabetes Care       Date:  1998-09       Impact factor: 19.112

5.  Direct medical costs of type 2 diabetes and its complications in Switzerland.

Authors:  Irmgard Schmitt-Koopmann; Matthias Schwenkglenks; Giatgen A Spinas; Thomas D Szucs
Journal:  Eur J Public Health       Date:  2004-03       Impact factor: 3.367

6.  The direct medical cost of type 2 diabetes.

Authors:  Michael Brandle; Honghong Zhou; Barbara R K Smith; Deanna Marriott; Ray Burke; Bahman P Tabaei; Morton B Brown; William H Herman
Journal:  Diabetes Care       Date:  2003-08       Impact factor: 19.112

7.  Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

8.  The economic impact of diabetes.

Authors:  B Jönsson
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

9.  Cost-effectiveness of prevention and treatment of the diabetic foot: a Markov analysis.

Authors:  Monica Maria Ortegon; William Ken Redekop; Louis Wilhelmus Niessen
Journal:  Diabetes Care       Date:  2004-04       Impact factor: 19.112

10.  Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.

Authors:  William H Hernan; Michael Brandle; Ping Zhang; David F Williamson; Margaret J Matulik; Robert E Ratner; John M Lachin; Michael M Engelgau
Journal:  Diabetes Care       Date:  2003-01       Impact factor: 19.112

  10 in total
  2 in total

Review 1.  The Economic Costs of Type 2 Diabetes: A Global Systematic Review.

Authors:  Till Seuring; Olga Archangelidi; Marc Suhrcke
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

2.  Pancreatic cancer mortality in Serbia from 1991-2010 - a joinpoint analysis.

Authors:  Milena Ilić; Hristina Vlajinac; Jelena Marinković; Nikola Kocev
Journal:  Croat Med J       Date:  2013-08       Impact factor: 1.351

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.